DXCM250117C81000
- 3.37
- 0.000.00%
DexCom Newsroom
DexCom (NASDAQ:DXCM) Delivers Shareholders Decent 8.1% CAGR Over 5 Years, Surging 5.2% in the Last Week Alone
Should We Be Delighted With DexCom, Inc.'s (NASDAQ:DXCM) ROE Of 34%?
Barclays Maintains DexCom(DXCM.US) With Hold Rating, Maintains Target Price $92
Raymond James Maintains DexCom(DXCM.US) With Buy Rating, Maintains Target Price $99
DXCM's Preliminary Results Show Strong Growth: How to Play the Stock?
Barclays Maintains DexCom(DXCM.US) With Hold Rating, Cuts Target Price to $92
Barclays Adjusts DexCom Price Target to $92 From $113, Maintains Equal Weight Rating
How Dexcom and ŌURA Are Unifying Two Distinct Market Sectors
United States Continuous Glucose Monitoring (CGM) Research Report 2025: Market to Grow by $4.7 Billion to Reach $8.4 Billion by 2033 With Abbott Laboratories, Dexcom, Medtronic, Senseonics Leading - ResearchAndMarkets.com
Why DexCom, Inc. (DXCM) Is Skyrocketing
Equities Fall as Markets Weigh Macro Data, Earnings
Lululemon To Rally Around 16%? Here Are 10 Top Analyst Forecasts For Thursday
This Netflix Analyst Turns Bullish; Here Are Top 5 Upgrades For Thursday
Express News | Dexcom Shares up 3.3% Premarket After Baird Upgrades to Outperform From Neutral, as per Thefly.com
Piper Sandler Maintains DexCom(DXCM.US) With Buy Rating, Maintains Target Price $90
Dexcom (DXCM) Receives a Buy From Piper Sandler
DexCom Analyst Ratings
Baird Upgrades DexCom(DXCM.US) to Buy Rating, Raises Target Price to $104
Stifel Maintains DexCom(DXCM.US) With Buy Rating, Maintains Target Price $100
Wells Fargo Maintains DexCom(DXCM.US) With Buy Rating, Maintains Target Price $94